Leflunomide and warfarin interaction: Case report and review of the literature

被引:16
作者
Chonlahan, Jennifer
Halloran, Mary Ann
Hammonds, Amy
机构
[1] Univ Oklahoma, Dept Pharm Clin & Adm Sci, Coll Pharm, Oklahoma City, OK 73117 USA
[2] Sanofi Aventis Pharmaceut, Bridgewater, NJ USA
来源
PHARMACOTHERAPY | 2006年 / 26卷 / 06期
关键词
leflunomide; warfarin; drug interaction; anticoagulation; international normalized ratio; INR;
D O I
10.1592/phco.26.6.868
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A 61-year-old Caucasian woman receiving long-term anticoagulation with warfarin for recurrent thromboembolism and atrial fibrillation was found to have an elevated international normalized ratio (INR) after she started leflunomide therapy for rheumatoid arthritis. Her INR had been stable for 4 months before this event. The patient required an overall decrease of 22% in her weekly warfarin dose to maintain a therapeutic INR within the goal range of 2.0-3.0 after adding leflunomide therapy. A comprehensive PubMed/MEDLINE search was conducted to identify literature addressing the potential interaction between warfarin and leflunomide. Evidence describing the interaction and its potential mechanism was limited to one published case report and to in vitro data, respectively Our case report provides additional support that such an interaction exists and that it was at least partly responsible for the subsequent increase in the patient's INR. Therefore, continued evaluation and documentation of this potential drug interaction is imperative. To reduce the risk of adverse effects related to excessive anticoagulation with the start of leflunomide in patients taking warfarin, clinicians should increase their frequency of INR monitoring and adjust the warfarin dosage accordingly to maintain therapeutic anticoagulation.
引用
收藏
页码:868 / 871
页数:4
相关论文
共 23 条
[1]   The pharmacology and management of the vitamin K antagonists [J].
Ansell, J ;
Hirsh, J ;
Poller, L ;
Bussey, H ;
Jacobson, A ;
Hylek, E .
CHEST, 2004, 126 (03) :204S-233S
[2]  
*AV PHARM INC, 2004, AR LEFL PACK INS
[3]   Leflunomide: mode of action in the treatment of rheumatoid arthritis [J].
Breedveld, FC ;
Dayer, JM .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (11) :841-849
[4]   PROTHROMBIN DURING WARFARIN TREATMENT [J].
BROZOVIC, M ;
GURD, LJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1973, 24 (05) :579-588
[5]   ANTAGONISTIC EFFECT OF ACTH AND CORTISONE ON THE ANTICOAGULANT ACTIVITY OF ETHYL BISCOUMACETATE [J].
CHATTERJEA, JB ;
SALOMON, L .
BRITISH MEDICAL JOURNAL, 1954, 2 (4891) :790-792
[6]  
Cohen S, 2001, ARTHRITIS RHEUM-US, V44, P1984, DOI 10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO
[7]  
2-B
[8]   Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone [J].
Costedoat-Chalumeau, N ;
Amoura, Z ;
Aymard, G ;
Sevin, O ;
Wechsler, B ;
Cacoub, P ;
Du, LTH ;
Diquet, B ;
Ankri, A ;
Piette, JC .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (08) :631-635
[9]  
Cropp JS, 1997, PHARMACOTHERAPY, V17, P917
[10]   A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis [J].
Emery, P ;
Breedveld, FC ;
Lemmel, EM ;
Kaltwasser, JP ;
Dawes, PT ;
Gömör, B ;
Van den Bosch, F ;
Nordström, D ;
Bjorneboe, O ;
Dahl, R ;
Horslev-Petersen, K ;
de la Serna, AR ;
Molloy, M ;
Tikly, M ;
Oed, C ;
Rosenburg, R ;
Loew-Friedrich, I .
RHEUMATOLOGY, 2000, 39 (06) :655-665